SETD9 (SET domain containing 9) is a lysine N-methyltransferase localized to the nucleoplasm and mitochondrion that functions in protein binding and regulation of signal transduction by p53 class mediators. In the context of ischemic stroke, SETD9 emerges as a key node in the lncRNA-mRNA co-expression network responding to butylphthalide treatment, with molecular docking analysis suggesting it as a potential direct therapeutic target 1. SETD9 holds clinical relevance in breast cancer pathology, where SNP variants at the MAP3K1/SETD9 locus (5q11.2) strongly associate with somatic PIK3CA variants in estrogen receptor α-positive breast cancers, with odds ratios reaching 2.97 2. Notably, both SNVs and PIK3CA variants coordinately elevate MAP3K1 and SETD9 expression levels, suggesting synergistic regulation through PIK3CA-dependent mechanisms. In psoriasis vulgaris, SETD9 represents one of five key characteristic genes of blood-heat syndrome (BHS), a traditional Chinese medicine classification, demonstrating high diagnostic efficacy in distinguishing psoriasis vulgaris syndromes through machine learning analysis 3. These findings indicate SETD9's pleiotropic roles across neurological, oncological, and inflammatory disease contexts, though direct molecular mechanisms beyond its methyltransferase activity require further characterization.